Shin Nippon Biomedical Laboratories, Ltd. (FRA:YB3)
Germany flag Germany · Delayed Price · Currency is EUR
10.00
+0.50 (5.26%)
At close: Nov 28, 2025

Shin Nippon Biomedical Laboratories Company Description

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, engages in the pharmaceutical development, transactional research, and medipolis businesses in Japan and internationally.

It offers non-clinical testing and non-clinical regulatory consulting for the development of pharmaceuticals, medical devices, or regenerative medicine products, including safety and pharmacology testing, and pharmacokinetic studies.

The company also engages in licensing activities for proprietary products which utilize unique intranasal formulation delivery technology, discovery of future seeds, and business promotion activities; and development of artificial seed production for Japanese eels.

In addition, it operates hotels accommodations facilities under the Villa Amafuru Oka and HOTEL Freesia names; and develops and operates geothermal and hot spring thermal power plants.

Shin Nippon Biomedical Laboratories, Ltd. was founded in 1957 and is headquartered in Kagoshima, Japan.

Shin Nippon Biomedical Laboratories, Ltd.
CountryJapan
Founded1957
IndustryCommercial Physical and Biological Research
Employees1,436
CEORyoichi Nagata

Contact Details

Address:
2438 Miyanoura-cho
Kagoshima, 891-1394
Japan
Phone81 9 9294 2600
Websitesnbl.co.jp

Stock Details

Ticker SymbolYB3
ExchangeFrankfurt Stock Exchange
Stock TypeCommon Stock
Fiscal YearApril - March
Reporting CurrencyJPY
SIC Code8731

Key Executives

NamePosition
Ryoichi NagataChief Executive Officer
Ryoichi NagataChief Financial Officer
Toshiyuki IwataHead of Investor Relations